Kuramoto H, Jobo T, Kato Y, Tateoka K, Sato R
Dept. of Obstetrics & Gynecology, Kitasato University School of Medicine. Sagamihara, Japan.
Gan To Kagaku Ryoho. 1996 May;23(6):673-7.
Various hormone therapies for endometrial carcinoma have been reported in the literature using progestins, tamoxifen (anti-estrogen), danazol, Gn-RH etc. The response rates of these hormone therapies are reported to be approximately 30%, which is no longer superior to other types of treatment methods. On the other hand, endometrial carcinoma is considered to be one of hormone dependent tumors. Although sex steroid hormones play an important role in the mechanism of carcinogenesis and the progression of early and well-differentiated endometrial carcinoma, most of the advanced carcinomas treated by hormone therapy have transformed into hormone independent state. It is expected that endometrial hyperplasia and well-differentiated carcinoma especially in younger patients should be effective materials for hormone therapy.
文献中报道了多种用于子宫内膜癌的激素疗法，包括使用孕激素、他莫昔芬（抗雌激素）、达那唑、促性腺激素释放激素等。据报道，这些激素疗法的有效率约为30%，已不再优于其他类型的治疗方法。另一方面，子宫内膜癌被认为是激素依赖性肿瘤之一。虽然性甾体激素在早期高分化子宫内膜癌的致癌机制及进展中起重要作用，但接受激素治疗的大多数晚期癌已转变为激素非依赖状态。预计子宫内膜增生及高分化癌，尤其是年轻患者的此类病症，应是激素治疗的有效对象。
